Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this
Addition Therapeutics is developing PRINT™ technology, which combines the safety and scalability of RNA therapeutics with the multi-year durability of gene therapies. The company is initially focused on rare, life-threatening diseases with severe unmet needs, aiming to deliver functional cures through its pipeline of PRINTed genetic medicines.
Parse Score
#63 of 127 in Biopharma Research Platforms and Services
Sources
biopharmadive.com shapes more of what AI says about Addition Therapeutics than any other source, at 100% of its citations.
The market map
Biopharma Research Platforms and Services →Where AI ranks Addition Therapeutics